by | Feb 21, 2025 | Lupus Foundation of America, News & Events
People with systemic lupus erythematosus (SLE) often face irreversible organ damage due to uncontrolled disease activity, frequent disease flares, and long-term glucocorticoid treatment. A recent study evaluated the effectiveness of anifrolumab (Saphnelo®) combined...
by | Feb 21, 2025 | Lupus Foundation of America
“Not even water?” This is one of the most common questions Muslims receive when fasting during Ramadan. No, we cannot eat or drink while fasting. But Ramadan is the most beautiful and awaited month of the year for Muslims. However, for individuals with chronic health...
by | Feb 7, 2025 | Lupus Foundation of America, News & Events
The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to Adicet Bio’s ADI-001 for refractory systemic lupus erythematosus (SLE) with extrarenal involvement (when a disease affects organs outside of the kidneys, like the heart, liver or...
by | Feb 7, 2025 | Lupus Foundation of America, News & Events
The New England Journal of Medicine has published a detailed analysis of Genentech’s positive results from the Phase III REGENCY study of Gazyva® (Obinutuzumab) for people with active lupus nephritis (LN). The study was supported by the Lupus Foundation of...
by | Feb 5, 2025 | Lupus Foundation of America
Black History Month is a time to honor the strength, resilience, and contributions of the Black community. This year, we’re focusing on the theme “Your Voice, Your Power” to highlight the importance of self-advocacy in healthcare settings.Self-advocacy means using...
by | Feb 4, 2025 | Lupus Foundation of America, News & Events
In a new study published in Lupus Science & Medicine, researchers assessed clinical trial perceptions among a predominantly Black cohort of participants with systemic lupus erythematosus (SLE). Researchers surveyed 767 participants from the GOAL cohort, the...
